Spring Bank Pharmaceuticals $SBPH, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer and inflammatory diseases announced third quarter results of 2016. For the recently concluded quarter, which ended September 30, 2016, net loss of was $4.1 million or $0.53 per basic and diluted share as compared to a net loss of $3.4 million or $0.59 per basic and diluted share for the same period in 2015.